Keros Therapeutics price target lowered to $44 from $77 at Scotiabank

Scotiabank analyst Greg Harrison lowered the firm’s price target on Keros Therapeutics (KROS) to $44 from $77 and keeps an Outperform rating on the shares. Shares of the stock are down following the announcement of a safety signal that emerged in its Phase 2 TROPOS trial of cibotercept, KER-012, in pulmonary arterial hypertension, the analyst tells investors. While the cardiac side effect related to the safety signal is cause for concern, the firm believes there is a potential for the 1.5 mg/kg dose to move forward if it can prove to be both safe and effective.